BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20461440)

  • 1. A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.
    Dickson MA; Rathkopf DE; Carvajal RD; Grant S; Roberts JD; Reid JM; Ames MM; McGovern RM; Lefkowitz RA; Gonen M; Cane LM; Dials HJ; Schwartz GK
    Invest New Drugs; 2011 Oct; 29(5):1004-12. PubMed ID: 20461440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.
    Dickson MA; Shah MA; Rathkopf D; Tse A; Carvajal RD; Wu N; Lefkowitz RA; Gonen M; Cane LM; Dials HJ; Schwartz GK
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1113-21. PubMed ID: 20953860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
    Tan AR; Headlee D; Messmann R; Sausville EA; Arbuck SG; Murgo AJ; Melillo G; Zhai S; Figg WD; Swain SM; Senderowicz AM
    J Clin Oncol; 2002 Oct; 20(19):4074-82. PubMed ID: 12351605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.
    Fakih MG; Fetterly G; Egorin MJ; Muindi JR; Espinoza-Delgado I; Zwiebel JA; Litwin A; Holleran JL; Wang K; Diasio RB
    Clin Cancer Res; 2010 Jul; 16(14):3786-94. PubMed ID: 20463088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
    Senderowicz AM; Headlee D; Stinson SF; Lush RM; Kalil N; Villalba L; Hill K; Steinberg SM; Figg WD; Tompkins A; Arbuck SG; Sausville EA
    J Clin Oncol; 1998 Sep; 16(9):2986-99. PubMed ID: 9738567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.
    Ramaswamy B; Phelps MA; Baiocchi R; Bekaii-Saab T; Ni W; Lai JP; Wolfson A; Lustberg ME; Wei L; Wilkins D; Campbell A; Arbogast D; Doyle A; Byrd JC; Grever MR; Shah MH
    Invest New Drugs; 2012 Apr; 30(2):629-38. PubMed ID: 20938713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.
    Fouladi M; Park JR; Stewart CF; Gilbertson RJ; Schaiquevich P; Sun J; Reid JM; Ames MM; Speights R; Ingle AM; Zwiebel J; Blaney SM; Adamson PC
    J Clin Oncol; 2010 Aug; 28(22):3623-9. PubMed ID: 20606092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.
    Bible KC; Lensing JL; Nelson SA; Lee YK; Reid JM; Ames MM; Isham CR; Piens J; Rubin SL; Rubin J; Kaufmann SH; Atherton PJ; Sloan JA; Daiss MK; Adjei AA; Erlichman C
    Clin Cancer Res; 2005 Aug; 11(16):5935-41. PubMed ID: 16115936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.
    Ramalingam SS; Parise RA; Ramanathan RK; Lagattuta TF; Musguire LA; Stoller RG; Potter DM; Argiris AE; Zwiebel JA; Egorin MJ; Belani CP
    Clin Cancer Res; 2007 Jun; 13(12):3605-10. PubMed ID: 17510206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.
    Shah MA; Kortmansky J; Motwani M; Drobnjak M; Gonen M; Yi S; Weyerbacher A; Cordon-Cardo C; Lefkowitz R; Brenner B; O'Reilly E; Saltz L; Tong W; Kelsen DP; Schwartz GK
    Clin Cancer Res; 2005 May; 11(10):3836-45. PubMed ID: 15897584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol.
    Thomas JP; Tutsch KD; Cleary JF; Bailey HH; Arzoomanian R; Alberti D; Simon K; Feierabend C; Binger K; Marnocha R; Dresen A; Wilding G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):465-72. PubMed ID: 12451473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.
    Whitlock JA; Krailo M; Reid JM; Ruben SL; Ames MM; Owen W; Reaman G;
    J Clin Oncol; 2005 Dec; 23(36):9179-86. PubMed ID: 16361620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients.
    LaCerte C; Ivaturi V; Gobburu J; Greer JM; Doyle LA; Wright JJ; Karp JE; Rudek MA
    Clin Cancer Res; 2017 Jul; 23(14):3592-3600. PubMed ID: 28174232
    [No Abstract]   [Full Text] [Related]  

  • 14. A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors.
    Deming DA; Ninan J; Bailey HH; Kolesar JM; Eickhoff J; Reid JM; Ames MM; McGovern RM; Alberti D; Marnocha R; Espinoza-Delgado I; Wright J; Wilding G; Schelman WR
    Invest New Drugs; 2014 Apr; 32(2):323-9. PubMed ID: 24114123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
    Byrd JC; Lin TS; Dalton JT; Wu D; Phelps MA; Fischer B; Moran M; Blum KA; Rovin B; Brooker-McEldowney M; Broering S; Schaaf LJ; Johnson AJ; Lucas DM; Heerema NA; Lozanski G; Young DC; Suarez JR; Colevas AD; Grever MR
    Blood; 2007 Jan; 109(2):399-404. PubMed ID: 17003373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial.
    Luke JJ; D'Adamo DR; Dickson MA; Keohan ML; Carvajal RD; Maki RG; de Stanchina E; Musi E; Singer S; Schwartz GK
    Clin Cancer Res; 2012 May; 18(9):2638-47. PubMed ID: 22374332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of flavopiridol in relapsed multiple myeloma.
    Hofmeister CC; Poi M; Bowers MA; Zhao W; Phelps MA; Benson DM; Kraut EH; Farag S; Efebera YA; Sexton J; Lin TS; Grever M; Byrd JC
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):249-57. PubMed ID: 24241210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.
    Holkova B; Supko JG; Ames MM; Reid JM; Shapiro GI; Perkins EB; Ramakrishnan V; Tombes MB; Honeycutt C; McGovern RM; Kmieciak M; Shrader E; Wellons MD; Sankala H; Doyle A; Wright J; Roberts JD; Grant S
    Clin Cancer Res; 2013 Apr; 19(7):1873-83. PubMed ID: 23515411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916).
    Muscal JA; Thompson PA; Horton TM; Ingle AM; Ahern CH; McGovern RM; Reid JM; Ames MM; Espinoza-Delgado I; Weigel BJ; Blaney SM
    Pediatr Blood Cancer; 2013 Mar; 60(3):390-5. PubMed ID: 22887890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.
    Schelman WR; Traynor AM; Holen KD; Kolesar JM; Attia S; Hoang T; Eickhoff J; Jiang Z; Alberti D; Marnocha R; Reid JM; Ames MM; McGovern RM; Espinoza-Delgado I; Wright JJ; Wilding G; Bailey HH
    Invest New Drugs; 2013 Dec; 31(6):1539-46. PubMed ID: 24114121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.